Clinical Trial Data: Efficacy of Femoston and Baoqing Granules for Perimenopausal Symptoms

An 8-week randomized, double-blind, placebo-controlled trial involving perimenopausal women. The study, registered with the Chinese Clinical Trial Registry (ChiCTR2300073338), compared the efficacy of Femoston plus Baoqing granules against Femoston plus placebo. Outcomes measured include the Modified Kupperman Menopausal Index, TCM syndrome scores, quality of life, sleep quality, anxiety, depression, and serum hormone levels.

Use Cases

• Analyzing the short-term efficacy of a traditional Chinese medicine adjunct based on Modified Kupperman Menopausal Index scores.
• Comparing multidimensional symptom relief between treatment groups based on MENQOL, PSQI, SAS, and SDS scores.
• Investigating the relationship between herbal therapy and serum hormone levels based on estradiol and follicle-stimulating hormone measurements.
• Evaluating the safety profile of a combined therapy based on hepatic/renal function tests and adverse-event monitoring.

Strengths

• Data originates from a registered, randomized, double-blind, placebo-controlled clinical trial (ChiCTR2300073338).
• Multidimensional outcomes were measured, including KMI, TCM scores, MENQOL, PSQI, SAS, SDS, and serum biomarkers.
• The study reports a specific safety outcome: only one mild adverse event was reported.

Limitations

• The dataset is a 46.3 KB DOCX file, suggesting limited scope and likely containing summary results rather than raw patient-level data.
• Row count and column-level documentation are absent; field semantics must be inferred from the text description.
• The study duration was 8 weeks; the description notes longer-term studies are needed to confirm durability of benefit.

Provenance

Source

figshare, authored by Chun Li.

Collection Method

Data collected from a randomized clinical trial.

Time Range

Trial duration was 8 weeks (4-week treatment, 4-week follow-up).

Freshness

Last updated 2026-04 04:36:51.

Geography

Likely China, based on trial registration with the Chinese Clinical Trial Registry.